Dose Insider / Glossary / Cholelithiasis

CholelithiasisGallstones and what GLP-1 trials found

Updated November 20, 2026 路 3 min read 路 WEGOVY and ZEPBOUND labels; Chiang et al., Gastroenterology 2025

Cholelithiasis is the name doctors sometimes use for gallstones: hard, pebble-like pieces, usually made of cholesterol or bilirubin, that form in the gallbladder.1 GLP-1 medicines raise the risk.

3.8%Wegovy, teenagers, Wegovy, gallstones reported
Gallstones reportedLabel weight trials, % of patientsWEGOVY, TEENAGERSWegovy3.8%Placebo0%WEGOVY, ADULTSWegovy1.6%Placebo0.7%ZEPBOUND, ADULTSZepbound1.1%Placebo1%Gallstones reportedLabel weight trials, % of patientsWEGOVY, TEENAGERSWegovy3.8%Placebo0%WEGOVY, ADULTSWegovy1.6%Placebo0.7%ZEPBOUND, ADULTSZepbound1.1%Placebo1%

Rapid weight loss raises the risk; the drugs add to it.

On this page

In the adult weight trials of Wegovy, gallstones were reported by 1.6% on the injection against 0.7% on placebo; in its teenage trial, by 3.8% against none on placebo.2 A 2025 analysis of 55 placebo-controlled trials put the increase across the class at a risk ratio of 1.46, about 2 more cases for every 1,000 people.3

What gallstones are

Gallstones range in size from a grain of sand to a golf ball, and they are common: NIDDK puts them at 10 to 15 percent of the U.S. population, almost 25 million people. Most cause no blockage and no pain; these silent gallstones usually need no treatment. When a stone blocks a bile duct, it can cause sudden pain in the upper right abdomen, called a gallbladder attack or biliary colic, often after a heavy meal and in the evening or at night.1

NIDDK lists who is more likely to get them: women, older people, people with a family history, and people with obesity, diabetes, insulin resistance or high triglycerides. It also names fast weight loss, such as after weight-loss surgery.1 Many people on GLP-1 medicines fit several of those groups before they start.

Why weight loss and these drugs matter

The Wegovy label explains part of the link: substantial or rapid weight loss can itself increase the risk of gallstones. It then adds the important point: gallbladder disease was more common on Wegovy than on placebo even after accounting for how much weight people lost.2 The Zepbound label says acute gallbladder events in its trials were associated with weight reduction.4 So both explanations apply: the weight loss raises the risk, and the medicines appear to add something on top.

The numbers on the labels

Trial groupGallstones, drugGallstones, placeboGallbladder inflammation, drugPlacebo
Wegovy injection, adults1.6%0.7%0.6%0.2%
Wegovy tablets, adults2.5%1%Not givenNot given
Wegovy injection, ages 12 to 173.8%0%0.8%0%
Zepbound, adults1.1%1%0.7%0.2%

WEGOVY label section 5; ZEPBOUND label section 5.4.2,4

In the Zepbound trials, gallbladder removal was reported in 0.2% on the drug and in no one on placebo, and similar rates of gallstones were seen in the weight trials and in the sleep apnea trials.4 The teenage numbers stand out: in STEP TEENS, five teenagers on semaglutide, 4%, had gallstones and none on placebo.5

Gallstones can inflame the gallbladder, called cholecystitis, and they can travel into the ducts. NIDDK names gallstones as the most common cause of acute pancreatitis, when a stone passes through and gets stuck in a bile or pancreatic duct.6 That is one reason the labels list both gallbladder disease and pancreatitis among their warnings.2,4

When to seek care

NIDDK advises seeing a doctor right away for these signs during or after a gallbladder attack: abdominal pain lasting several hours, nausea and vomiting, fever or chills, yellowing of the skin or eyes, tea-colored urine and light-colored stools. They may signal a serious infection or inflammation of the gallbladder, liver or pancreas.1

What the labels ask

The Zepbound label asks prescribers to inform patients of the risk of acute gallbladder disease and to tell them to contact their healthcare provider if it is suspected. If gallstones or gallbladder inflammation are suspected, both labels call for gallbladder studies and clinical follow-up.2,4 Our page on stomach pain on a GLP-1 sets out which pain needs a doctor quickly.

Sources

  1. National Institute of Diabetes and Digestive and Kidney Diseases. Definition and facts for gallstones; Symptoms and causes of gallstones. Last reviewed November 2017, read November 20, 2026. niddk.nih.gov
  2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 5 and 6.1. accessdata.fda.gov
  3. Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology 2025;169:1268-1281. doi:10.1053/j.gastro.2025.06.003
  4. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 5.4 and 17. accessdata.fda.gov
  5. Weghuber D, Barrett T, Barrientos-P茅rez M, et al. Once-weekly semaglutide in adolescents with obesity (STEP TEENS). N Engl J Med 2022;387:2245-2257. doi:10.1056/NEJMoa2208601
  6. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and causes of pancreatitis. Last reviewed November 2017, read November 20, 2026. niddk.nih.gov

Related analyses

Log belly pain with your doses and weight, so your doctor sees the whole picture.

Open Dose Insider